C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema

Angioedema Clinical Trial

Official title:

Pharmacokinetics, Clinical Efficacy and Safety of C1 Inhibitor Concentrate (C1-Esteraseremmer-N) for the Treatment of Hereditary (and Acquired) Angioedema

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00125541
• Other study ID #: KB2003.01C
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: July 29, 2005
• Last updated: May 1, 2009
• Start date: November 2006
• Est. completion date: May 2008

Study information

• Verified date: May 2009
• Source: Sanquin
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
• Study type: Interventional

Clinical Trial Summary

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.

Description:

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In part C of the study, a number of HAE patients will be treated prophylactically with open-label C1-esteraseremmer-N for a period of 16 weeks. The number of attacks occurring will be compared with historical data. If possible, also some patients treated prophylactically with C1 inhibitor for acquired angioedema will be included.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 6
• Est. completion date: May 2008
• Est. primary completion date: April 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 16 Years and older

Eligibility

Inclusion Criteria:

Inclusion criteria for hereditary angioedema patients:

• Established diagnosis of hereditary angioedema type I or II: markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4.

• Patients already using C1 inhibitor concentrate for prophylaxis of angioedema attacks.

• Age = 16 years

• Signed informed consent by patient and patient's legal representative if under 18 years old

Inclusion criteria for acquired angioedema patients:

• Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4.

• Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life.

• Age = 16 years

• Patient already using C1 inhibitor concentrate for prophylaxis of angioedema attacks

• Signed informed consent by patient and patient's legal representative if under 18 years old

Exclusion Criteria:

Exclusion criteria for hereditary angioedema patients:

• Use of angioedema prophylactic medication during the study, other than C1-esteraseremmer-N.

• Change in oral contraceptives starting from the last two months before the start of the trial until the end of the study period.

• Presence of clinically relevant C1 inhibitor auto antibodies

• Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than in part A of this protocol.

• Usage of heparin starting from the last two days prior to the study until the end of the study period.

• B-cell malignancy

• Pregnancy or lactation

• History of allergic reaction to C1 inhibitor concentrate or other blood products

Exclusion criteria for acquired angioedema patients:

• Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study

• Usage of heparin within the last two days prior to the study

• Pregnancy or lactation

• History of allergic reaction to C1 inhibitor concentrate or other blood products

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Angioedema

Intervention

Drug:
• C1 inhibitor concentrate (C1-esteraseremmer-N)
every 5-7 days

Locations

Country	Name	City	State
Netherlands	Academic Medical Centre	Amsterdam

Sponsors (1)

Lead Sponsor	Collaborator
Sanquin

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary objective in this clinical study is to evaluate the prevention of angioedema attacks in patients prophylactically treated with C1-esteraseremmer-N.		16 weeks	Yes
Secondary	The secondary objective of this study is to evaluate the safety and clinical activity of C1-esteraseremmer-N.		16 weeks	Yes